



MEN

FIRST CANCER SITE
**MYELOID
LEUKAEMIAS**

**MYELOID LEUKAEMIAS
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**LEUCEMIA MIELOIDE
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	7431		9849		9849		7431		4298		1254		395		7431	9849
Person-years ▶	18857		20251		1394		4621		9109		3776		1350		18857	20251
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND MYELOID LEUKAEMIAS	252	0.99	348	1.25	96	3.83	53	0.72	134	1.10	50	1.15	15	0.97	-0.10	3.41
HEAD AND NECK	20	1.82	22	1.83	2	1.98	4	1.29	9	1.69	4	2.09	3	4.33	0.48	0.49
ORAL CAVITY	7	2.66	8	2.79	1	4.27	0	0.00	3	2.37	2	4.24	2	11.44	0.23	0.25
PHARYNX	1	0.41	2	0.76	1	4.86	0	0.00	1	0.86	0	0.00	0	0.00	-0.08	-0.03
LARYNX	12	2.01	12	1.84	0	0.00	4	2.32	5	1.73	2	2.00	1	2.85	0.32	0.27
OESOPHAGUS	3	1.10	5	1.68	2	7.58	0	0.00	2	1.52	1	2.18	0	0.00	0.02	0.10
STOMACH	15	0.98	16	0.94	1	0.60	3	0.65	11	1.47	1	0.41	0	0.00	-0.02	-0.05
COLON RECTUM	36	1.04	58	1.52	22	6.40	7	0.70	19	1.15	8	1.34	2	0.94	0.07	0.98
COLON	17	0.72	34	1.31	17	7.26	5	0.74	6	0.53	4	0.98	2	1.37	-0.35	0.40
RECTUM	19	1.72	24	1.98	5	4.57	2	0.63	13	2.46	4	2.11	0	0.00	0.42	0.59
LIVER	5	0.49	7	0.62	2	1.98	2	0.67	3	0.61	0	0.00	0	0.00	-0.28	-0.21
GALLBLADDER	2	0.74	3	1.00	1	3.50	0	0.00	2	1.53	0	0.00	0	0.00	-0.04	0.00
PANCREAS	4	0.58	5	0.66	1	1.46	0	0.00	3	0.91	1	0.86	0	0.00	-0.15	-0.13
LUNG	45	1.02	68	1.40	23	5.16	14	1.07	19	0.89	11	1.52	1	0.40	0.05	0.96
SKIN MELANOMA	8	2.00	9	2.08	1	3.10	1	0.99	4	2.12	3	3.76	0	0.00	0.21	0.23
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
KAPOSI SARCOMA	3	4.95	4	6.02	1	17.00	0	0.00	3	10.21	0	0.00	0	0.00	0.13	0.16
SOFT TISSUE	0	0.00	1	0.94	1	11.36	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	0.00
BONE	0	0.00	1	3.26	1	39.83	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	0.03
BREAST	2	3.60	2	3.28	0	0.00	1	6.36	1	3.76	0	0.00	0	0.00	0.08	0.07
PROSTATE	38	0.78	46	0.86	8	1.69	8	0.58	23	1.00	5	0.58	2	0.63	-0.56	-0.36
TESTIS	0	0.00	1	1.16	1	23.10	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	0.01
KIDNEY AND RENAL PELVIS	16	1.99	21	2.39	5	6.82	7	3.17	6	1.57	3	2.05	0	0.00	0.42	0.60
BLADDER AND URINARY TRACT	21	0.74	33	1.06	12	4.20	1	0.12	14	1.03	4	0.85	2	1.22	-0.38	0.10
URINARY BLADDER	21	0.78	33	1.11	12	4.39	1	0.13	14	1.08	4	0.89	2	1.27	-0.32	0.16
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.06
BRAIN AND CENTRAL NERVOUS SYSTEM	6	1.89	8	2.31	2	7.07	1	1.15	3	1.98	1	1.73	1	4.74	0.15	0.22
THYROID	5	3.36	6	3.77	1	9.41	0	0.00	2	2.89	1	3.16	2	15.50	0.19	0.22
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	11	1.45	14	1.69	3	4.30	2	0.96	6	1.66	2	1.47	1	2.03	0.18	0.28
MYELOMA	2	0.60	5	1.35	3	8.84	1	1.02	1	0.62	0	0.00	0	0.00	-0.07	0.06
LEUKAEMIAS	1	0.17	4	0.60	3	4.87	0	0.00	0	0.00	1	1.00	0	0.00	-0.27	-0.13
LYMPHOID LEUKAEMIAS	0	0.00	2	0.63	2	6.84	0	0.00	0	0.00	0	0.00	0	0.00	-0.15	-0.06
MYELOID LEUKAEMIAS	1	0.37	1	0.33	0	0.00	0	0.00	0	0.00	1	2.19	0	0.00	-0.09	-0.10
OTHER LEUKAEMIAS	0	0.00	1	2.09	1	20.63	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	0.03
OTHER AND ILL DEFINED SITES	10	0.75	10	0.68	0	0.00	1	0.26	3	0.46	5	2.25	1	1.33	-0.18	-0.23

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
**MYELOID
LEUKAEMIAS**

MYELOID LEUKAEMIAS
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LEUCEMIA MIELOIDE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	6364	8572		8572		6364		3716		1224		374		6364	8572
Person-years ▶	17351	18553		1202		3981		8313		3644		1414		17351	18553	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND MYELOID LEUKAEMIAS	141	1.02	179	1.19	38	3.15	31	0.87	65	0.97	28	1.05	17	1.74	0.12	1.51
HEAD AND NECK	3	1.67	4	2.05	1	6.65	0	0.00	1	1.16	1	2.82	1	7.52	0.07	0.11
ORAL CAVITY	3	3.18	4	3.90	1	12.22	0	0.00	1	2.21	1	5.45	1	14.64	0.12	0.16
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.03
OESOPHAGUS	1	1.57	1	1.43	0	0.00	1	5.83	0	0.00	0	0.00	0	0.00	0.02	0.02
STOMACH	10	1.30	11	1.30	1	1.25	2	0.92	7	1.85	1	0.77	0	0.00	0.13	0.14
COLON RECTUM	26	1.28	28	1.26	2	1.05	5	0.92	11	1.12	4	1.06	6	4.56	0.32	0.31
COLON	19	1.31	20	1.26	1	0.73	4	1.03	8	1.14	2	0.74	5	5.30	0.26	0.22
RECTUM	7	1.20	8	1.25	1	1.85	1	0.64	3	1.06	2	1.85	1	2.69	0.07	0.09
LIVER	3	0.88	5	1.33	2	5.87	0	0.00	2	1.20	0	0.00	1	4.92	-0.02	0.07
GALLBLADDER	4	1.45	4	1.31	0	0.00	1	1.29	2	1.48	0	0.00	1	6.49	0.07	0.05
PANCREAS	5	0.98	5	0.89	0	0.00	0	0.00	1	0.41	3	3.21	1	3.05	-0.01	-0.03
LUNG	8	0.96	14	1.55	6	8.19	3	1.41	1	0.25	1	0.62	3	4.98	-0.02	0.27
SKIN MELANOMA	3	1.01	4	1.25	1	4.69	0	0.00	2	1.42	1	1.58	0	0.00	0.00	0.04
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
KAPOSI SARCOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	30	0.78	40	0.97	10	3.40	2	0.22	14	0.76	12	1.54	2	0.67	-0.48	-0.07
CERVIX UTERI	2	0.91	3	1.27	1	5.82	0	0.00	1	0.94	1	2.35	0	0.00	-0.01	0.03
CORPUS UTERI	3	0.45	5	0.70	2	3.78	0	0.00	2	0.63	0	0.00	1	2.11	-0.21	-0.11
OVARY	3	0.66	3	0.61	0	0.00	0	0.00	2	0.91	1	1.13	0	0.00	-0.09	-0.10
KIDNEY AND RENAL PELVIS	5	1.56	8	2.29	3	10.81	3	3.66	1	0.65	1	1.61	0	0.00	0.10	0.24
BLADDER AND URINARY TRACT	6	1.22	6	1.12	0	0.00	4	3.04	2	0.84	0	0.00	0	0.00	0.06	0.03
URINARY BLADDER	4	0.87	4	0.80	0	0.00	3	2.45	1	0.45	0	0.00	0	0.00	-0.03	-0.05
URINARY TRACT	2	5.96	2	5.42	0	0.00	1	11.03	1	6.18	0	0.00	0	0.00	0.10	0.09
BRAIN AND CENTRAL NERVOUS SYSTEM	3	1.46	3	1.35	0	0.00	0	0.00	3	3.04	0	0.00	0	0.00	0.05	0.04
THYROID	7	2.04	8	2.20	1	4.94	2	2.83	3	1.88	1	1.27	1	2.96	0.21	0.24
HODGKIN LYMPHOMA	1	1.99	1	1.86	0	0.00	1	8.76	0	0.00	0	0.00	0	0.00	0.03	0.02
NON-HODGKIN LYMPHOMA	7	1.37	9	1.62	2	4.50	4	3.06	2	0.81	1	1.01	0	0.00	0.11	0.19
MYELOMA	2	0.88	4	1.61	2	9.35	0	0.00	2	1.82	0	0.00	0	0.00	-0.02	0.08
LEUKAEMIAS	0	0.00	1	0.27	1	3.12	0	0.00	0	0.00	0	0.00	0	0.00	-0.19	-0.14
LYMPHOID LEUKAEMIAS	0	0.00	1	0.62	1	7.01	0	0.00	0	0.00	0	0.00	0	0.00	-0.08	-0.03
MYELOID LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.10
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	9	0.93	12	1.13	3	3.17	3	1.15	6	1.28	0	0.00	0	0.00	-0.04	0.08

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio